The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has asked Bharat Biotech for additional data on its COVID-19 vaccine, Covaxin, for administering it to children aged between 2-12 years, said sources.
This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12 years. No recommendations have been made as of now, sources told news agency .
However, the SEC, after a meeting on Thursday (April 21), has recommended restricted emergency use of Biological E's COVID-19 vaccine, Corbevax, in children aged 5-12 years, said sources.
Now, DCGI will be giving approval for its emergency use authorisation. The Corbevax vaccine is currently being administered to children in the age group of 12-14 years. The vaccination drive for children in the age group of 15-18 years commenced on January 3 this year.
They are being administered Covaxin. The drive later expanded on March 16 to include children aged between 12-14 years. They are being administered Corbevax.
Overall, India is currently administering two COVID-19 vaccines to children above 12 years.
Leave a comment
Your email address will not be published. Required fields are marked *